Five Valsartan Lawsuits Selected for Second Round of Bellwether Trials
Selections have been made in case the parties fail to negotiate Valsartan cancer settlements following a first round of bellwether trials expected to begin in late 2025.
Selections have been made in case the parties fail to negotiate Valsartan cancer settlements following a first round of bellwether trials expected to begin in late 2025.
Parties will meet with the MDL judge today, to discuss issues scheduling the remaining bellwether trials selected by the Court.
California jury agreed that Boehringer Ingelheim's heartburn drug was dangerous, but was split on whether Zantac caused the bladder cancer diagnosis.
First bellwether trial in the valsartan MDL will involve claims brought by an Alabama man diagnosed with liver cancer, which is the most commonly reported injury caused by the recalled blood pressure drug.
More than 1,270 Valsartan lawsuits are currently awaiting trial, most involving plaintiffs diagnosed with cancer following exposure to the recalled blood pressure drug, who are getting sicker and many are dying.
Zantac settlement must still be approved by individual plaintiffs, but is expected to resolve vast majority of cancer lawsuits filed in state courts.
Nitrosamine contamination has resulted in massive recalls for valsartan, Zantac and other medications, as well as lawsuits by users who developed cancer.
Drug maker is challenging a lower court ruling, which allows Zantac lawsuits in Delaware to move forward to trial over the increased risk of cancer caused by the recalled heartburn medication.
Florida ruling does not directly impact other Zantac lawsuits filed against GlaxoSmithKline in other state courts, each involving claims that former users were not adequately warned about the cancer risks that led to a 2020 recall.
Defense verdict comes as GSK faces several additional Zantac trials in Florida, Pennsylvania and Nevada in the coming months, each raising similar allegations that the recalled heartburn drug caused cancer to develop in former users.